The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
复制标题
DOI：
10.3747/co.v16i4.469
复制
发表时间：
2009-08
期刊：
影响因子：
--
通讯作者：
Pritchard K
中科院分区：
文献类型：
--
作者：
Dent S;Verma Sh;Latreille J;Rayson D;Clemons M;Mackey J;Verma S;Lemieux J;Provencher L;Chia S;Wang B;Pritchard K
The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (her2), was the first her2-targeted therapy that clearly demonstrated a significant clinical benefit for women with her2-overexpressing metastatic breast cancer (mbc). However, in recent years it has become increasingly apparent that, when trastuzumab is used in the first-line setting in combination with chemotherapy, most women eventually develop progressive disease. Determining the treatment options available to women who have progressed while on trastuzumab therapy has been hampered by a paucity of high-quality published data. In addition, with the standard use of trastuzumab in the adjuvant setting (for eligible her2-positive patients), the role of anti-her2 agents for patients who experience a breast cancer relapse has become a clinically relevant question. This manuscript reviews current available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other her2-targeted agents in two key mbc indications: Treatment for women with her2-positive mbc progressing on trastuzumab (that is, treatment beyond progression) Treatment for women with her2-positive mbc recurring following adjuvant trastuzumab (that is, re-treatment) The suggestions set out here will continue to evolve as data and future trials with trastuzumab and other her2-targeted agents emerge.
